ClinicalTrials.gg
RecruitingNCT07738432Updated Oct 19, 2026

Neuro-MoD: Neuroplasticity With Motor Development

An interventional study of Constraint-Induced Movement Therapy (CIMT) and Transcutaneous auricular vagus nerve stimulation (taVNS) in Perinatal Brain Injury, sponsored by University of Wisconsin, Madison. Recruiting at 1 site in United States. Open to participants aged 8 Months to 24 Months. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by University of Wisconsin, Madison · Not applicable, Interventional, and Treatment

How we know

Updated Oct 19, 2026Now RecruitingFirst site in United States+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
8 Months to 24 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 84 studies in Hypoxia-Ischemia, Brain with a site in United States — 27 open to participants now, 34 under way, 1 of them phase 3. Hypoxia-Ischemia, Brain · United States.

Planned enrollment
42nd of 52
8 · median 32
Started
2026
with 5 others
No phase
21 of 84
6 open now
Primary completion
2027-06
later than 15 of 33 live
Registered
82nd of 84
by date
Lead sponsor
4 of 84
University of Wisconsin, Madison

Among the 84 studies in Hypoxia-Ischemia, Brain with a site in United States, this one is the 42nd largest by planned enrollment of the 52 interventional ones that give a count, is one of 6 that started in 2026, is one of 21 with no phase, reaches primary completion later than 15 of the 33 other live ones, and was the 82nd registered.

Hypoxia-Ischemia, Brain

261 studies on the registry are indexed under Hypoxia-Ischemia, Brain; 93 are open to participants now.

Browse Hypoxia-Ischemia, Brain studies →

Open to participants now

27 of the 84 studies in Hypoxia-Ischemia, Brain with a site in United States are open now. Recruiting first, the newest first:

21 more — sign in →

All 27 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 59 Hypoxia-Ischemia, Brain studies recruiting now, 21 (36%) set no upper age limit and 36 (61%) stop at 75 or younger; 46 take children under 18; 7 take healthy volunteers.

This study: 8 Months to 24 Months · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 84 studies in Hypoxia-Ischemia, Brain with a site in United States, or all of them as a file.
02

Study summary

This study is for infants and toddlers between 8 and 24 months old who use one arm and/or hand differently following a perinatal brain injury. This is a time when investigators think they can best help improve how the brain controls movement. Investigators are testing whether the combination of transcutaneous auricular vagus nerve stimulation (taVNS) with 40 hours of constraint-induced movement therapy (CIMT) can help infants move their weaker arm and hand better and make the brain pathways for movement stronger.

Read the detailed description

Primary Objective • To evaluate the feasibility of using spTMS to elicit motor-evoked potentials (MEPs) in infants with hemiplegic cerebral palsy (CP) due to perinatal brain injury and to determine whether baseline MEP characteristics predict motor response to a 40-hour intervention combining taVNS with CIMT.

Exploratory Objective:

  • To investigate neuroplastic changes in cortical motor circuitry associated with taVNS-paired CIMT by examining longitudinal changes in MEP topography and corresponding motor function.
03

Conditions studied

  • Perinatal Brain Injury

Keywords

  • hypoxic-ischemic encephalopathy (HIE)
  • perinatal stroke
  • intracranial hemorrhage
  • hemiplegic cerebral palsy (CP)
  • Constraint-Induced Movement Therapy (CIMT)
  • transcutaneous auricular vagus nerve stimulation (taVNS)
  • motor-evoked potentials (MEPs)
  • Single Pulse Transcranial Magnetic Stimulation (spTMS)
04

Who can participate

Ages eligible
8 Months to 24 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Infants aged 8 to 24 months, diagnosed with hemiplegia or with an evident unilateral upper-limb weakness due to perinatal brain injury
  • Gross Motor Function Classification System (GMFCS) level I-IV
  • Infants who have not received previous CIMT in the preceding 3 months
  • Able to make consecutive appointments for assessments and intervention over 2 weeks, and complete the 3-month follow-up.

Exclusion criteria

Exclusion Criteria:

  • GMFCS level V
  • Prior CIMT within the past 3 months
  • Severe motor impairment/quadriplegic involvement.
  • Uncontrolled seizure disorders, cardiomyopathy, severe congenital malformations,
  • significant sensory impairments, or conditions preventing safe participation in therapy sessions
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (estimated)

Study arms

  • Experimental
    Infants and Toddlers with Perinatal Brain Injury

    Therapy sessions in this study will take 4 hours a day, 5 days a week for 2 weeks (40 hours total CIMT). Sticker like sensors (electrodes) are placed just inside and outside the child's left earlobe at the start of the session to deliver the taVNS. During daily therapy sessions, the taVNS will be on whenever the child moves their free arm, for up to 2.5 minutes at a time.

    Behavioral: Constraint-Induced Movement Therapy (CIMT) · Device: Transcutaneous auricular vagus nerve stimulation (taVNS)

Interventions

  • BehavioralConstraint-Induced Movement Therapy (CIMT)

    CIMT involves placing a mitt constraint on the stronger arm and hand while encouraging your child to use the weaker arm and hand during intensive therapy sessions.

  • DeviceTranscutaneous auricular vagus nerve stimulation (taVNS)

    Stimulates a nerve by the ear, called the vagus nerve, that may enhance learning motor skills.

06

What researchers measure

Primary outcomes

  1. Proportion of participants in whom MEPs can be elicited reliably at baseline (presence/absence)

    Motor-evoked potentials (MEPs) are electrical responses recorded from a muscle following a brief magnetic pulse delivered to the brain using single-pulse transcranial magnetic stimulation (spTMS). This outcome measures the proportion of participants in whom a reliable MEP can be elicited at baseline and serves as a measure of the feasibility of assessing corticospinal connectivity in infants with perinatal brain injury.

    Time frame: baseline (Day 1)

  2. Completion rate of spTMS sessions

    This outcome measures the proportion of planned spTMS assessment sessions that are successfully completed at baseline, post-intervention, and 3-month follow-up. Completion rates will be used to evaluate the feasibility, tolerability, and practicality of conducting repeated spTMS assessments in infants and toddlers with perinatal brain injury.

    Time frame: baseline (Day 1), post-intervention (Day 12), 3 month follow-up

Secondary outcomes

  1. Baseline MEP Amplitude

    MEP amplitude will be reported in millivolts (mV), measured from electromyography recordings of the target muscle.

    Time frame: baseline (Day 1), post-intervention (Day 12), 3 month follow-up

  2. Percent change in Mini-Assisting Hand Assessment (mini-AHA) score from baseline to end of treatment

    The mini-AHA evaluates how effectively infants with unilateral upper extremity impairment use their affected hand during bimanual play activities. Scores are reported on a standardized 0-100 scale, with higher scores indicating greater functional use of the affected hand and lower scores indicating less functional use.

    Time frame: baseline (Day 1), post-intervention (Day 12), 3 month follow-up

  3. Change in Quality of Upper Extremity Skills Test (QUEST) score from baseline

    This is a measure of movement, scored in several domains: dissociated movement (joint mobility), grasp (holding and manipulating objects), protective extension (reflex reactions), and weight bearing assessments. It is scored from 0 to 100 where higher scores mean better movement. Change in QUEST score from baseline will be used to assess changes in upper extremity function following the intervention.

    Time frame: baseline (Day 1), post-intervention (Day 12), 3 month follow-up

  4. Bayley Scales of Infant Development (Bayley-4; Fine Motor subtest)

    The Bayley Scales of Infant and Toddler Development, Fourth Edition (Bayley-4) Fine Motor subtest evaluates fine motor skills, including reaching, grasping, object manipulation, and hand-eye coordination. Scores are standardized based on age and range from 1 to 19, with a normative mean of 10 and standard deviation of 3. Scores in the range of 8-12 are generally considered within the typical range for age. Higher scores indicate more advanced motor development.

    Time frame: baseline (Day 1), post-intervention (Day 12), 3 month follow-up

  5. Bayley Scales of Infant Development (Bayley-4; Gross Motor subtests)

    The Bayley Scales of Infant and Toddler Development, Fourth Edition (Bayley-4) Gross Motor subtest evaluates gross motor skills, including posture, sitting, crawling, standing, walking, and other age-appropriate movement abilities. Scores are standardized based on age and range from 1 to 19, with a normative mean of 10 and standard deviation of 3. Scores in the range of 8-12 are generally considered within the typical range for age. Higher scores indicate more advanced motor development.

    Time frame: baseline (Day 1), post-intervention (Day 12), 3 month follow-up

  6. Gross Motor Function Measure (GMFM-88)

    The Gross Motor Function Measure-88 (GMFM-88) evaluates gross motor function across five domains: lying and rolling, sitting, crawling and kneeling, standing, and walking, running, and jumping. Items are scored on a 4-point scale and converted to dimension and total scores ranging from 0 to 100. Higher scores indicate better gross motor function and greater ability to perform age-appropriate motor activities.

    Time frame: baseline (Day 1), post-intervention (Day 12), 3 month follow-up

Other outcomes

  1. MEP Amplitude

    Motor-evoked potential (MEP) amplitude measures the strength of the muscle response produced after a brief magnetic pulse is applied to the brain using single-pulse transcranial magnetic stimulation (spTMS). Larger amplitudes indicate stronger communication between the brain and the target muscle. MEP amplitude will be reported in millivolts (mV).

    Time frame: baseline (Day 1), post-intervention (Day 12), 3 month follow-up

  2. MEP Threshold

    Motor-evoked potential (MEP) threshold is the minimum level of magnetic stimulation needed to produce a muscle response. Lower thresholds generally indicate that the pathway between the brain and muscle can be activated more easily. MEP threshold will be reported as a percentage of maximum stimulator output (%MSO).

    Time frame: baseline (Day 1), post-intervention (Day 12), 3 month follow-up

  3. Cortical Map Topography

    Cortical map topography describes the location and distribution of brain areas that produce muscle responses when stimulated using single-pulse transcranial magnetic stimulation (spTMS). Changes in the size, location, or organization of these areas over time may reflect changes in brain connectivity and neuroplasticity.

    Time frame: baseline (Day 1), post-intervention (Day 12), 3 month follow-up

07

Study locations

1 of 1 sites recruiting
  • University of Wisconsin - Madison
    Madison, Wisconsin 53715, United States
    Recruiting
    • Bernadette Gillick, PhD, MSPT · Contactbgillick@wisc.edu · 608-262-7457
    • Bernadette Gillick, PhD, MSPT · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Jun 2027, 8 months later.

Of 46 non-industry interventional studies with no phase under Hypoxia-Ischemia, Brain, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 63. This study's planned 8 months is below that.

Counting every sponsor, half of 47 studies reached it within 33 months; a quarter within 19 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 27, 2026
First posted
Jul 31, 2026
StartEst.
Oct 2026
Primary completionEst.
Jun 2027
CompletionEst.
Jun 2027
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 19, 2026
Sites
1 site added — first site in United States
Show site
  • University of Wisconsin - Madison · Madison, United States
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in United States
    Show site
    • University of Wisconsin - Madison · Madison, United States

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07738432
Responsible party
Sponsor
First posted
Jul 31, 2026
Start date
Oct 2026 (estimated)
Primary completion
Jun 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Oct 19, 2026

Study contacts

Bernadette Gillick, PhD, MSPT
Contact
bgillick@wisc.edu
608-262-7457
Arun Karumattu Manattu, PhD
Contact
karumattuman@wisc.edu
608-381-2699
Bernadette Gillick, PhD, MSPT
principal investigator · UW School of Medicine and Public Health

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion